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Abstract 
Mendelian diseases have shown to be an efficient model for connecting genotypes 
to phenotypes and for elucidating the function of genes. Whole-exome sequencing 
(WES) accelerated the study of rare Mendelian diseases in families, allowing for 
directly pinpointing rare causal mutations in genic regions without the need for 
linkage analysis. However, the low diagnostic rates of 20-30% reported for 
multiple WES disease studies point to the need for improved variant pathogenicity 
classification and causal variant prioritization methods. Here we present eDiVA 
(http://ediva.crg.eu), an automated computational framework for identification of 
causal genetic variants (coding/splicing SNVs and InDels) for rare diseases using 
WES of families or parent-child trios. eDiVA combines NGS data analysis, 
comprehensive functional annotation, and causal variant prioritization optimized 
for familial genetic disease studies. eDiVA features a machine learning based 
variant pathogenicity predictor combining various genomic and evolutionary 
signatures. Clinical information, such as disease phenotype or mode of inheritance, 
is incorporated to improve the precision of the prioritization algorithm. 
Benchmarking against state of the art competitors demonstrates that eDiVA 
consistently performed as good or better than existing approaches in terms of 
detection rate and precision. Moreover, we applied eDiVA to several familial 
disease cases to demonstrate its clinical applicability. 
Keywords: NGS Diagnostics, rare genetic disease, machine learning, whole exome 
sequencing, disease variant prioritization  
Introduction 
Rare genetic diseases are classical models for studying gene function and linking 
genotypes to disease phenotypes. Although each of these diseases only affects a 
small number of patients, the sum of people affected by one of the more than 7000 
rare diseases exceeds 30 million individuals in the US alone (Cutting, 2014). 
Whole-exome sequencing (WES), and more recently whole genome sequencing 
(WGS), are routinely applied to identify variants causing rare Mendelian diseases 
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in studies of families or parent-child trios (Choi et al., 2009; Ng et al., 2010; Louis-
Dit-Picard et al., 2012; Rabbani et al., 2012).   
Usually, each exome sequencing experiment yields tens of thousands of genetic 
variants in coding and splicing regions that require thorough functional annotation 
and filtering to allow identification of the causal variant. Several tools have been 
published performing variant annotation, including Annovar, VEP, or SNPeff, 
which augment the sequencing information with a comprehensive set of current 
omics, population genomics and clinical knowledge (Wang et al., 2010; Cingolani 
et al., 2012; McLaren et al., 2016). These tools utilize a large selection of available 
databases containing gene annotations, various genomic features, variant allele 
frequencies in different populations, functional impact prediction, and evolutionary 
conservation (Bao et al., 2014). Other methods, such as eXtasy (Sifrim et al., 
2013), PhenoDB (Sobreira et al., 2015), Phen-Gen (Javed et al., 2014), VarSifer 
(Teer et al., 2012), KGGseq (Li et al., 2012), and SPRING (Wu et al., 2014), focus 
on prioritization of potentially causal variants using both functional annotation and 
clinical information. These tools systematically filter, evaluate, and prioritize 
thousands of variants, taking into account knowledge found in genome annotation 
databases (Rhead et al., 2010) , disease gene repositories (OMIM - Online 
Mendelian Inheritance in Man; Landrum et al., 2014) and patient pedigree 
information, as well as phenotype descriptions and disease definitions provided e.g. 
as Human Phenotype Ontology (HPO) terms (Köhler et al., 2014). Finally, 
methods such as Endeavour (Tranchevent et al., 2008) and GeneDistiller (Seelow 
et al., 2008) prioritize disease genes, not individual variants, by integrating diverse 
genomic data sources. 
Detection rates of causal variants using WES have been reported to be as low as 
20% to 30% of cases (Yang et al., 2013; Lee et al., 2014), although higher success 
rates have been reported for specific disease or inheritance types (Sawyer et al., 
2016) and for studies using parent-child trios (Yang et al., 2013). While some of 
the unsolved cases might be explained by intergenic or intronic regulatory variation 
or unidentified structural variants, the low detection rate also indicates the need for 
development of better prioritization strategies for coding variants and robust 
classifiers comprehensively integrating the available amount of prior omics and 
disease knowledge.   
Many computational algorithms have been developed to assess pathogenicity of 
genetic variants. Tools such as SIFT (Kumar et al., 2009a), CADD (Kircher et al., 
2014), PolyPhen-2 (Adzhubei et al., 2010) or Eigen (Ionita-Laza et al., 2016) are 
commonly used in clinical practice to help variant interpretation. They derive a 
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functional impact score based on amino-acid or nucleotide conservation, and 
biochemical properties of the amino-acid changes as features. While some 
algorithms additionally categorize variants into various categories such as ‘neutral’, 
‘benign’ ‘deleterious’, ‘damaging’, ‘probably-damaging’, or ‘pathogenic’ (e.g. 
SIFT, Condel, PolyPhen-2 and Mutation Assessor), scores of other methods need 
to be interpreted by using (often arbitrary) cutoffs for pathogenicity (e.g. CADD). 
These predicted pathogenicity labels are an integral part of the American College 
of Medical Genetics and Genomics (ACMG) standards and guidelines for the 
interpretation of sequence variants (Richards et al., 2015). Methods combining 
multiple classifiers, such as MetaLR, have been shown to produce better results 
than single classifiers (Dong et al., 2015). Recently, specialized ensemble learning 
methods for estimating pathogenicity of rare variants have been published: M-CAP 
(Jagadeesh et al., 2016), using gradient boosting trees on pathogenicity scores and 
conservation features, and Revel (Ioannidis et al., 2016), using a random forest to 
integrate several pathogenicity predictors.  
To combine an intuitive user interface with comprehensive variant prediction, 
annotation, pathogenicity classification and causal variant prioritization we 
developed eDiVA (exome Disease Variant Analysis), http://www.ediva.crg.eu. The 
eDiVA pipeline is composed of four main components: 1) eDiVA-Predict, where 
sequencing results are processed to predict the presence of genomic variants; 2) 
eDiVA-Annotate, that enriches variants via a domain-knowledge database; 3) 
eDiVA-Score, which estimates variant pathogenicity using a random forest model; 
and 4) eDiVA-Prioritize, in which variants from small groups of related samples 
(i.e. families or parent-child trios) are analyzed jointly. eDiVA returns a shortlist of 
candidate variants compatible with the selected disease inheritance model and the 
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pedigree information. Using the pathogenicity probability computed by eDiVA-
Score, variants are ranked such that better candidates appear on top of the result 
list. eDiVA has been developed with specific emphasis on usability, automation 
and reproducibility of results and is available as a web-service with a graphical user 
interface (see Supplemental Material), or as an open source repository with Docker 
containers. eDiVA can be run using the NextFlow (Di Tommaso et al., 2017) 
pipeline management system to ensure its compatibility with most stand-alone or 
cloud computing platforms as well as to guarantee reproducibility on any system.  
eDiVA has been optimized for two common clinical diagnostics scenarios, parent-
child-trios comprised of healthy parents and one affected child (tested for 
recessive, compound heterozygous and X-linked inheritance or dominant de novo 
variants) and families with multiple affected relatives (additionally tested for 
dominant inheritance). We demonstrate that eDiVA outperforms competing 
approaches in a semi-synthetic benchmark study introducing thousands of known 
disease variants from ClinVar (Landrum et al., 2014) or HGMD (Stenson et al., 
2017) into real WES data from the 1000 Genomes Project CEPH parent–offspring 
trio of European ancestry (NA12878, NA12891, NA12892). We furthermore report 
summary statistics on eDiVA and Phen-Gen results for 35 unreported disease 
cases, composed of 15 cases of spinocerebellar ataxia, 16 cases of primary 
immunodeficiency, and 4 cases of congenital myasthenia. 
Methods  
eDiVA pipeline  
eDiVA consists of a Python pipeline combined with an SQL Database back-end 
composed of four components: variant prediction, variant annotation, pathogenicity 
estimation and variant prioritization (Supp. Figure S1). The main functionality of 
eDiVA is to process Next Generation Sequencing (NGS) data for small sets of 
samples (e.g. families or parent-child trios) and to output a shortlist of potentially 
causal variants for the diagnosed disease. eDiVA is available as an open source 
repository, https://github.com/mbosio85/ediva, with a Docker container 
composition wrapped within a NextFlow (Di Tommaso et al., 2017) interface to 
guarantee exact reproducibility on the most common computing platforms 
(including several cloud platforms) and as a freely accessible web server: 
http://www.eDiVA.crg.eu. The modular nature of eDiVA allows for easy 
integration of specific parts, e.g. the eDiVA-Score module for pathogenicity 
estimation, in other pipelines or tools. Comprehensive examples for the use of 
eDiVA and example input files are included in the repository and on the website.   
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eDiVA-Predict: WES or WGS processing and variant calling  
The eDiVA-Predict module performs sample-wise variant calling according to the 
recent GATK (McKenna et al., 2010) best practices 
(https://www.broadinstitute.org/gatk/guide/best-practices as of June 2017) to 
extract genetic variants from raw reads. Reads in fastq format are aligned using 
bwa-mem (Li, 2013), alignments are post-processed using samtools (Li, 2011), 
GATK (McKenna et al., 2010), Picard (Picard Tools - By Broad Institute), and 
custom quality filters (details provided in Supplemental Material). Finally, VCF 
files are generated using GATK HaplotypeCaller. Subsequent re-genotyping of all 
positions harboring a SNV or InDel in at least one family member yields a 
complete matrix of variants for the whole sample set (family) in multi-sample VCF 
format. Due to the computational resources required for read alignment and variant 
calling, eDiVA-Predict is currently not enabled on the eDiVA web server, but can 
be used with the stand-alone version of eDiVA on a local or remote computing 
infrastructure (e.g. Amazon Cloud). Alternatively, variant prediction can be 
performed using any tool able to produce one multi-sample VCF file reporting 
genotype quality and coverage information for all variable positions (e.g. GATK 
(McKenna et al., 2010), freebayes (Garrison and Marth, 2012)).  
eDiVA-Annotate: functional variant annotation  
Using the eDiVA-Annotate module each variant is individually linked with public 
information sources in order to integrate multiple knowledge domains, and to 
provide a comprehensive annotation profile. First, ANNOVAR (Wang et al., 2010) 
is applied to relate each variant to its corresponding gene (choosing among UCSC, 
Ensembl or Refseq gene annotations), and to its functional consequence at the 
protein level. Next, functional, population genomics and evolutionary data relevant 
for variant prioritization are added to each variant. To this end we created a 
MySQL database, eDiVA-DB, containing all relevant positional information 
obtained from UCSC table browser (Rhead et al., 2010) and other sources. Each 
variant is annotated with population allele frequency information from the dbSNP 
(Sherry et al., 2001), discovEHR (Dewey et al., 2016), 1000 Genomes Project 
(1000GP (The 1000 Genomes Project Consortium, 2015)), Exome Variant Server 
(Exome Variant Server), and GnomAD exomes (Lek et al., 2016) databases. The 
latter three databases also provide information on specific populations (e.g. 
Caucasian, Asian, African American etc.), which can be selected for improved 
causal variant prioritization. Information on evolutionary conservation is 
incorporated from PhyloP (Rhead et al., 2010), and PhastCons (Hubisz et al., 
2011), including conservation scores for primates, mammals and vertebrates. Pre-
calculated scores for functional impact of variants have been integrated based on 
the algorithms SIFT (Kumar et al., 2009b), PolyPhen-2 (Adzhubei et al., 2010), 
Mutation Assessor(Reva et al., 2011), Condel (González-Pérez and López-Bigas, 
2011), Eigen (Ionita-Laza et al., 2016), and CADD (Kircher et al., 2014). 
Furthermore, eDiVA-DB includes information on genomic features like segmental 
duplications and simple sequence repeats provided by UCSC table browser (Rhead 
et al., 2010). Finally, eDiVA-DB provides clinical data from ClinVar (Landrum et 
al., 2014) and OMIM (OMIM - Online Mendelian Inheritance in Man) related to 
each variant and affected gene.  
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eDiVA-Annotate uses multi-sample VCF files and returns a file with annotated 
variants in comma-separated value format. This step can be performed on the 
eDiVA web server.  
eDiVA-Score: estimating variant pathogenicity 
eDiVA’s prioritization algorithm relies on accurate estimation of pathogenicity for 
each variant. We therefore developed eDiVA-Score, a machine learning classifier, 
which assigns a pathogenicity probability to each variant based on its annotation 
characteristics obtained from eDiVA-Annotate. eDiVA-Score is built by training a 
random forest (RF) model using the R “randomForest” package with 1000 binary 
classification trees (Breiman, 2001; Hastie et al., 2009) and 5-fold cross validation. 
Eleven features were selected to train the RF model: a) the maximum Minor Allele 
Frequency (MAF) of 1000Genomes and GnomAD databases; b) four conservation 
measures (conservation in primates and mammals using the PhastCons (Hubisz et 
al., 2011) and PhyloP (Pollard et al., 2010)); c) four functional impact predictors 
(Condel (González-Pérez and López-Bigas, 2011), Phred-scaled CADD score 
(Kircher et al., 2014), Eigen (Ionita-Laza et al., 2016), and Mutation Assessor 
(Reva et al., 2011)); d) the likelihood to be in a segmental duplication, which 
correlates with false positive variant calls (Ho et al., 2011); and e) an in-house 
estimator of systematic sequencing errors called ABB-score (Muyas et al., 2019). 
Note that Condel, Eigen and CADD are combination scores integrating several 
features also included in eDiVA-score, namely evolutionary conservation 
(PhastCons and PhyloP in mammals and primates) and Mutation Assessor scores. 
The random forest model has been trained using 15,000 random pathogenic and 
likely pathogenic variants from the ClinVar database (Landrum et al., 2014) as 
positive cases. We then built a control set composed of 15,000 non-pathogenic 
variants from ClinVar, and 100,000 random variants from GnomAD (Lek et al., 
2016) not contained in ClinVar. The vast majority of variants in both positive and 
negative training set are rare (AF < 1%, Supp. Figure S2A, B), thus circumventing 
that AF dominates the classification model. Following the neutral theory of 
molecular evolution (Kimura 1983) missing data is generated using expected 
values for non-pathogenic (neutral) variants (Fig. 1). The only exception is AF, as 
missing data in the context of AF means that the SNV is novel, i.e. has AF of zero. 
Variants used for training of the RF have been excluded in all benchmarking tests 
performed in this study. 
eDiVA-Prioritize: causal variant prioritization  
Causal variant prioritization consists of four steps, 1) ranking by estimated 
probability of variants to cause a phenotypic change (eDiVA-Score, see above); 2) 
removal of all variants that do not segregate according to the selected inheritance 
mode; 3) filtering based on functional and population genomic features; and 4) 
prioritization based on user defined clinical phenotypes (as HPO IDs). Filtering 
based on segregation requires the user to submit a simple pedigree file defining the 
relationship between samples and their disease state (i.e. affected or unaffected), 
and to choose the most likely inheritance pattern for the disease (or to run all 
modes). eDiVA-Prioritize can process variants following five types of inheritance 
patterns: a) dominant de novo, b) autosomal-dominant inherited, c) autosomal-
recessive homozygous, d) autosomal-recessive compound heterozygous or e) X-
linked.   
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Optionally, eDiVA removes variants that are improbable of being damaging, are 
likely false positive calls or do not have sufficient read coverage in all family 
members to reliably estimate segregation patterns. By default, eDiVA applies a 
lenient filter setting defined in Supp. Table S1. Finally, eDiVA allows the user to 
specify a list of HPO terms (Köhler et al., 2014) relevant for the disease as an 
additional source of information to prioritize variants in genes. eDiVA highlights 
all variants in genes related to the submitted phenotypic traits using a custom 
algorithm to estimate the HPO-gene association (detailed in the Supplemental 
material).  
Performance evaluation using semi-synthetic cases 
To assess the performance of eDiVA and several competing methods, we 
implemented a semi-synthetic benchmark based on real WES data from a trio in 
which we spiked-in known pathologic variants from the ClinVar database 
(Landrum et al., 2014). We chose a publicly available CEPH trio sequenced within 
the framework of the 1000 Genomes Project composed of samples with European 
ancestry NA12878 (daughter), NA12891 and NA12892 (parents), downloadable 
from 
https://public_docs.crg.es/sossowski/MicrobeGenomes/human/eDiVA/insilico_sim
ulation_data/, and we called variants and generated a multi-sample VCF file using 
eDiVA-Predict. For the purpose of this benchmark study, all 138,705 variants 
found in the original trio are considered true negatives, i.e. variants not associated 
to disease. 
Next, we embedded known disease variants in the trio following segregation 
patterns expected for Mendelian diseases. This positive set, containing variants 
associated to diseases, consists of all variants from ClinVar (Landrum et al., 2014) 
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database labeled as “Pathogenic” or “Likely pathogenic”, having an OMIM 
reference in the database and that had not been used for training of eDiVA-Score. 
For each pathogenic variant, we extracted: chromosome, position, reference and 
alternative nucleotides, dbSNP identifier, gene name, inheritance mode of the 
associated disease (where available, randomly assigned otherwise), and HPO terms 
for the disease. Variants without HPO annotation have been excluded from the 
benchmark set.   
We have simulated three inheritance patterns: autosomal-recessive homozygous, 
autosomal-recessive compound heterozygous, and dominant de novo, as these are 
the most likely patterns found in parent-child trio based rare disease diagnostics. To 
create realistic disease genotypes, each pathogenic variant was introduced into the 
exomes of the daughter and the parents, if applicable according to the inheritance 
mode. The read distribution of reference and alternative reads was simulated 
depending on the inheritance mode and the original coverage data. The variant 
allele frequency (VAF) of the alternative allele (i.e. the fraction of reads showing 
the alternative allele) introduced in the original VCF file has been obtained using a 
beta distribution and a binomial distribution for homozygous and heterozygous 
variants, respectively. A total of 6,811 disease-associated variants from ClinVar not 
previously used in the training of eDiVA-Score were used for benchmarking: 3,353 
recessive homozygous, 2,592 dominant de novo, and 866 recessive compound 
heterozygous disease-causing variants (see Supp. Table S2 for additional 
information on simulated genotypes).   
Benchmarking of variant pathogenicity estimation methods  
We evaluated the ability of eDiVA-Score and six competing methods, namely 
CADD, Eigen, DANN, Revel, M-CAP and MetaLR ( Dong et al., 2015, Kircher et 
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al., 2014; Ioannidis et al., 2016; Ionita-Laza et al., 2016; Jagadeesh et al., 2016, 
Quang et al., 2015), to prioritize pathogenic over benign variants. We generated a 
Receiver Operating Characteristic (ROC) curve for each tool and benchmark set 
and measured performance by Area Under the Curve (AUC).  
First, we evaluated the performance of each method on the ClinVar test set 
(containing only variants not used for model training), using variants labeled 
‘pathogenic’ as true positives (TP) and variants labeled ‘benign’ as true negatives 
(TN) (Fig. 2A-C). Second, we benchmarked using variants from the HGMD and 
GnomAD databases (not used in model training or present in ClinVar) as TP and 
TN, respectively (Fig. 2D-F). Third, we measured the performance of all methods 
on HGMD data only, using the categories for damaging and likely damaging 
mutation (DM and DM?) as TP and any other HGMD category as FP (Fig. 3G-I). 
Functional impact values for the benchmarked methods have been obtained from 
the respective publications. CADD, DANN and eDiVA provide damage estimates 
for all positions of the genome, and Eigen for close to 70% of all positions, while 
Revel, M-CAP and MetaLR are trained specifically for rare (AF <1%) or known 
variants and are only available for a subset of ClinVar, HGMD and GnomAD. We 
therefore performed three separate performance tests for each of the three 
benchmark sets, applying the following criteria 1) using only variants having Revel 
and M-CAP scores available (ClinVar: 3,887 TP and 10,494 TN, 
HGMD/GnomAD: 63,712 TP and 100,000 TN, HGMD: 63,712 TP and 1,892 TN); 
2) random subset of all variants, assigning a default value of 0 to missing values 
(ClinVar: 19,888 TP and 16,694 TN, HGMD/GnomAD: 96,569 TP and 100,000 
TN, HGMD: 96,569 TP and 7376 TN); and 3) using only rare variants (AF <=0.01) 
This article is protected by copyright. All rights reserved. 
 A
cc
ep
te
d 
A
rt
ic
le
 
from the previous pool of variants (ClinVar: 16,531 TP and 15,531, 
HGMD/GnomAD: 90,004 TP and 97,828 TN, HGMD: 96,004 TP and 2,817 TN).  
Furthermore, we studied five variant sets provided by Grimm et al. (Grimm et al., 
2015), forming a collection of datasets for benchmarking pathogenicity classifiers 
published in independent studies. Finally, we combined these five sets to form a 
combined benchmark (see Supplemental Materials for details).   
Benchmarking of disease variant prioritization methods 
We compared eDiVA with three commonly used tools for variant annotation and 
prioritization: Exomiser (Robinson et al., 2014), PhenoDB (Sobreira et al., 2015) 
and Phen-Gen (Javed et al., 2014) on a set of 6,811 semi-synthetic parent-child 
trios (see above). PhenoDB was executed from the https://phenodb.org/ website 
using standard parameters a) AF <0.01; b) including variants which are present in 
dbSNP, and c) analysis type chosen among “autosomal-recessive compound 
heterozygous”, “autosomal-recessive homozygous”, or “autosomal-dominant new 
mutation”. We locally installed Phen-Gen and launched it with the corresponding 
setups: a) “Recessive”, “allow_de_novo=0” for recessive and compound 
inheritance, and b) “Dominant”, “allow_de_novo=1” for the dominant de novo 
inheritance model. We locally installed Exomiser and analyzed all trio cases using 
PhenIX prioritization mode (details in Supplemental Material). We tested eDiVA 
in two configurations, a) without phenotype description, and b) using HPO IDs 
describing the disease phenotype for disease-specific prioritization of candidate 
variants.   
To benchmark the ability of eDiVA, Exomiser, PhenoDB, and Phen-Gen to 
distinguish disease causing from benign variants we compared three quality 
metrics, a) recall (i.e. did the causal variant appear in the output list or not), b) 
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average number of false positives across all benchmarked cases as a proxy for 
precision, and c) ranks of causal variants reported for each mode of inheritance 
using violin plots (Figure 3A-C). In order to compare ranks, variants reported by 
eDiVA are sorted by eDiVA-Score, Phen-Gen results are sorted by DCOD-score 
(“Probability of deleteriousness based on genic predictor”), and Exomiser results 
are sorted by “Exomiser Gene Combined Score”. Results of PhenoDB are 
presented in the default order (chromosome and position), as no prioritization score 
is provided.  
Results  
eDiVA: a platform for pathogenicity estimation and causal variant 
prioritization  
eDiVA is a disease variant prioritization tool optimized for NGS based genetic 
disease diagnostics in families and parent child trios. It is composed of four 
components: eDiVA-Predict handles read alignment and variant prediction, 
eDiVA-Annotate performs functional annotation of variants, eDiVA-Score 
estimates the probability of variants to be pathogenic, and eDiVA-Prioritize filters 
and ranks variants according to various quality criteria, proper segregation, and 
likelihood to cause phenotypic changes. eDiVA is available as standalone software 
at https://github.com/mbosio85/ediva, and as a web-service providing access to 
functional annotation, pathogenicity classification and causal variant prioritization 
modules (www.ediva.crg.eu). The eDiVA web-service facilitates analysis of 
families or parent-child trios in a few clicks, requiring only a VCF file, and 
optionally a set of HPO IDs describing the disease phenotype. eDiVA returns a 
shortlist of candidate variants and genes, ranked by pathogenicity score (together 
with gene relatedness to the specified HPO IDs if available), and including all 
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annotation features in comma separated value (.csv) and Microsoft Excel (.xlsx) 
format. 
Benchmarking eDiVA and competing methods    
To comprehensively evaluate eDiVA’s performance in finding disease-causing 
variants, and to compare it to previously published tools, we performed a 
benchmark in two categories. First, we evaluated the ability of eDiVA-Score to 
distinguish disease causing from benign variants compared to four publicly 
available methods for estimating deleteriousness. Second, we benchmarked the 
performance of eDiVA, PhenoDB and Phen-Gen on identification of causal 
variants using semi-synthetic parent-child trios analyzed by WES, optionally 
allowing for the use of clinical phenotype descriptions for causal variant 
prioritization.   
Benchmarking of eDiVA-Score and other variant pathogenicity classifiers  
We developed eDiVA-Score, a machine learning based method for estimating 
variant pathogenicity (deleteriousness) independent of any prior clinical 
information (see Methods). Feature selection identified population allele frequency, 
functional impact and conservation in placental mammals as the most important 
features (Fig. 1A). The correlation matrix for all features is shown in Supp. Figure 
S3. Features selected for inclusion in the RF show distinct distributions for 
pathogenic variants compared to benign variants in ClinVar (Fig. 1B) and random 
coding variants reported in GnomAD (Supp. Figure S4B). All integrated 
conservation scores (PhyloP and PhastCons scores for vertebrates, mammals and 
primates) classify pathogenic variants better than random, but perform worse than 
any specialized method for estimating functional impact or pathogenicity (Supp. 
Figure S5).    
We benchmarked the ability of eDiVA-Score, CADD, DANN, Eigen, Revel, M-
CAP and MetaLR to predict the deleteriousness of variants and to distinguish 
pathogenic from benign variants in nine setups (Methods). We first compared the 
performance on classifying pathogenic and benign variants from ClinVar (Fig. 2A), 
and on distinguishing disease variants from HGMD (Stenson et al., 2017) from 
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100,000 random variants from GnomAD (Fig. 2D), for which scores are available 
for all methods. Note that Revel and M-CAP have been trained on a subset of the 
HGMD variants (e.g. using class ‘DM’ as positive training set), giving them an 
advantage due to potential overfitting in any of the following benchmark tests 
using HGMD variants (for an in-depth discussion of the interplay between 
overfitting and circularity in training and benchmarking data see Grimm et al. 
(Grimm et al., 2015). Using ROC analysis we found that eDiVA-Score 
distinguishes disease causing and benign variants with high sensitivity and recall in 
both benchmark sets (area under the curve (AUC) of 0.95 and 0.90), considerably 
better than CADD (AUC of 0.91 and 0.74), DANN (AUC of 0.89 and 0.82), Eigen 
(AUC of 0.87 and 0.77), Revel (AUC of 0.91 and 0.89), M-CAP (AUC of 0.84 and 
0.90) and MetaLR (AUC of 0.88 and 0.87). Notably, eDiVA-Score showed better 
precision-recall curves than competing methods (Supp. Figure S6).  
Disease variant prioritization tools depend on pathogenicity values for any position 
of the exome, since de novo mutations can occur randomly and novel ultra-rare 
variants are still being discovered. Therefore, we next benchmarked the methods on 
random variants chosen from the complete ClinVar and HGMD/GnomAD 
benchmark sets, while setting missing data to benign (Methods). As expected, the 
recall of Revel, M-CAP and MetaLR decreased substantially due to missing 
information, while the other methods performed slightly better than in the previous 
tests (Fig. 2B, E). Finally, we tested how the methods perform on classification of 
rare variants (AF <0.01), otherwise following the same criteria for selection of the 
test sets as in the previous benchmark (Fig. 2C, F). Again, eDiVA-Score shows the 
best performance of all methods.   
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We wondered if the use of random GnomAD variants as true negative (non-
pathogenic) set might bias the results of the HGMD/GnomAD benchmark due to 
e.g. over-fitting onto the allele frequency feature. Therefore, we next measured the 
performance of all methods on HGMD data only, using the categories for highly 
likely pathogenic (‘DM’ and ‘DM?’) as TP set and less likely pathogenic (any 
other HGMD category) as TN set (Methods). We performed the same three tests as 
discussed above for the ClinVar and HGMD/GnomAD benchmark sets. On the 
subset of variants for which scores are available for all methods (Fig. 2G) eDiVA’s 
performance (AUC 0.77) was found to be slightly lower than MetaLR’s (0.80), 
Revel’s (AUC 0.82) and M-CAP’s (AUC 0.85), but substantially better than the 
performance of the other general-purpose methods CADD (AUC 0.67) and Eigen 
(AUC of 0.70). However, eDiVA still outperformed all other methods on the 
complete HGMD variant set (missing scores set to benign), as well as on the rare 
variant set (Fig. 2H and I).  
Finally, we compared the performance of all methods on a benchmark set compiled 
by Grimm et al. (Grimm et al., 2015), consisting of mutually exclusive subsets of 
the previously published benchmark sets Varibench, HumVar, ExoVar, 
predictSNP, and SwissVar (see Supplemental Material for details). These popular 
benchmark datasets differ in the way they define pathogenic and neutral variants, 
e.g. the maximum AF for pathogenic variants can differ dramatically, allowing us 
to benchmark diverse challenges. Furthermore, Grimm et al. filtered these 
benchmark sets in order to minimize overlap between them, reducing the likelihood 
that tools are benchmarked on variants they have been trained on, and hence 
reducing the impact of overfitting on the benchmark results (Grimm et al., 2015). 
We found that none of the methods consistently performs better than other 
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methods, but that eDiVA-Score, M-CAP, Revel and MetaLR show comparably 
high performance, except on PredictSNP and Varibench, for which MetaLR, Revel 
and M-CAP show a better performance than eDiVA-Score. PredictSNP 
incorporates HGMD variants in the positive and negative control sets (see Table 2 
and 3 of Grimm et al. (Grimm et al., 2015)), likely giving a strong advantage to 
Revel and M-CAP, which have been trained on HGMD. CADD, DANN and Eigen 
performed significantly worse than the other three methods on all benchmark sets. 
Note that CADD, DANN, Eigen, and MetaLR have been trained to predict 
deleteriousness (or more general the functional impact) of variants, while eDiVA-
Score, Revel and M-CAP have been trained to identify pathogenic variants, partly 
explaining the divergent performance levels across the different benchmark sets. 
Moreover, eDiVA-score, MetaLR, and M-CAP use CADD as one of many 
features, explaining the better performance of the derived scores.  
In summary, our benchmark results demonstrate the good performance of eDiVA-
Score as pathogenicity classifier, comparable to and often better than state-of-the-
art methods available to date. Furthermore, eDiVA-Score outperforms other 
general-purpose methods not restricted by variant AF (i.e. CADD, DANN, and 
Eigen), while showing competitive results when compared with specialized tools 
such as MetaLR, M-CAP and Revel, which are only available for known (rare) 
SNVs.   
Causal variant prioritization in parent-child trios  
We benchmarked the performance of eDiVA and three widely used tools, 
PhenoDB, Phen-Gen and Exomiser, on identification of causal variants for rare 
Mendelian diseases in parent-child trios. To this end, we simulated three scenarios 
typically encountered in parent-child trio diagnostics, a) autosomal dominant de 
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novo, b) autosomal recessive homozygous, and c) autosomal recessive compound 
heterozygous Mendelian inheritance modes. In total, we simulated 6,811 semi-
synthetic parent-child trios by integrating reported pathogenic variants from 
ClinVar into real WES data of a trio obtained from 1000GP (see Methods and 
Supp. Table S2).  
We benchmarked the ability of the tools to identify causal pathogenic variants 
following a given segregation pattern and to rank causal variants as high as 
possible, while reporting as few as possible other (false positive) variants. As 
performance metrics, we used recall (i.e. if the causal variant was reported), the 
average number of false positives in the output list as a proxy for precision, and the 
rank of the causal variant in the output list, which represents the ease of finding the 
right candidate for the user. eDiVA consistently shows the best recall of all 
methods for all modes of inheritance across 6,811 simulated parent-child trios, 
missing an average of 12% of causal variants, followed by Exomiser, Phen-Gen, 
and PhenoDB missing on average 20%, 28% and 31% of causal variants, 
respectively (Figure 4B). eDiVA also achieves higher precision, i.e. reports on 
average fewer FP than Exomiser, Phen-Gen or PhenoDB in all scenarios (Figure 
4C). A limitation of the benchmark set is that all 6,811 semi-synthetic trios use the 
same original CEPH trio as background. Hence, the space of potential FPs is the 
same for each simulated case. However, the actual FPs reported by each tool 
depend on inheritance mode and simulated disease, given that HPO based 
phenotypic descriptions are leveraged.  
Figure 3A shows violin plots with the rank distribution of causal variants in the 
output lists of 6,811 analyzed trios. The optimal result is a skewed distribution 
close to 0, meaning that the causal variant is reported as first or very close to the 
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top of the list in the majority of cases. Here, comparison with PhenoDB is not 
meaningful, as PhenoDB (unlike Phen-Gen, Exomiser and eDiVA), offers no 
ranking based on pathogenicity scores (but sorts by chromosome and position). 
Compared to Exomiser and Phen-Gen, eDiVA’s ranking method shows the best 
performance for recessive homozygous inheritance, eDiVA and Exomiser show 
best performance for dominant de novo inheritance, and all tools show similarly 
good performance for compound heterozygous inheritance. eDiVA consistently 
reported causal recessive homozygous variants and compound heterozygous 
variants within the top 5 candidates (median = 1), and dominant de novo variants 
within the top 25 of reported candidates (median = 4) (Fig. 4A). Considering that 
the CEPH trio has been sequenced as part of the 1000GP we finally tested if the 
use of 1000GP allele frequency information for filtering biases the performance 
estimates of eDiVA. However, we found no difference when not using the 1000GP 
AF database (Supp. Figure S7). Nonetheless, we cannot exclude the possibility that 
eDiVA (or the other methods) show reduced performance in understudied 
populations.   
The use of HPO IDs for prioritization further reduced FPs reported by eDiVA 
(label eDiVA-HPO in Fig. 4C). Overall, we observed a twofold reduction in FPs 
across all inheritance modes tested. However, filtering by in-silico gene panels also 
resulted in a reduction in recall (Fig. 4B and C). Finally, we observed improved 
prioritization ranks under all inheritance types, with the strongest impact seen for 
de novo variants (Fig. 4A).  
We also investigated the impact of incomplete or imperfect phenotyping on 
eDiVA’s performance by altering the HPO annotation of genetic variants imported 
from ClinVar (see Supplemental Methods). Benchmarking results on the semi-
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synthetic simulation with incomplete phenotyping show a small reduction in causal 
gene ranking efficiency (Supp. Figure S8). However, even imperfect phenotypic 
information improved the performance as compared to complete exclusion of such 
information.  
In summary, the benchmark analyses show that eDiVA achieves highly 
competitive causal variant prioritization performance with respect to ranking, 
precision and recall, while requiring no fine-tuning of parameters by the user for 
specific inheritance types. When disease-specific HPO term descriptors are 
available, eDiVA’s precision is further enhanced to the point at which complete 
automation of causal variant identification is feasible for recessive homozygous 
and compound heterozygous segregation.   
eDiVA results on clinical cases 
eDiVA has successfully been used in published case studies on mitral valve 
prolapse (Durst et al., 2015), cystic fibrosis (Ramos et al., 2014), phenylketonuria 
(Trujillano et al., 2014), arthrogryposis (Wambach et al., 2017) and Opitz-C 
(Urreizti et al., 2017), among others, identifying both known as well as novel rare 
disease genes. We recently assessed the performance of eDiVA for the diagnosis of 
rare congenital genetic diseases using WES of 35 parent-child trios, including 15 
cases of congenital ataxia, 4 cases of congenital myasthenia, and 16 cases of 
primary immunodeficiency. Here we report general statistics on the number of 
candidate genes per case, while case reports and novel candidate genes will be 
published in separate papers. Across the 35 studied trios, eDiVA on average 
reported a median of 11, 3, 10 candidate genes per trio for recessive homozygous, 
recessive compound heterozygous and dominant de novo inheritance mode, 
respectively, using default parameters. In comparison, Phen-Gen reported a median 
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of 36 and 52 candidate genes for recessive (including compound heterozygous) and 
dominant (including de novo) inheritance mode, respectively. Histograms of 
reported candidate gene numbers for eDiVA and Phen-Gen are shown in Supp. 
Figure S9 and S10. eDiVA found causal variants in known genes for the respective 
disease in 9 cases, and variants in genes associated to closely related disease 
phenotypes in 7 cases. Screening of Phen-Gen results did not reveal additional 
candidates missed by eDiVA. The function of a novel disease variant for congenital 
ataxia has been described in Bahamonde et al. (Bahamonde et al., 2015), and 
reports for other candidate genes are in preparation 
Discussion  
Despite the massive increase in sequencing capacity and the availability of highly 
optimized analysis tools, multiple large-scale rare disease studies reported that in 
only 20-30% of cases a causal variant can be identified using WES. Several 
reasons might explain the inability of WES analysis to identify causal variants in a 
majority of cases, including e.g. the inability to identify regulatory variants 
(Claussnitzer et al., 2015), our limited knowledge of the function of noncoding 
RNAs, generation of new exon donor or acceptor sites by intronic variants (Lee et 
al., 2012), small copy number variations (Krumm et al., 2012), incomplete 
penetrance and unknown function of coding genes, among others. However, we 
argue that the potential of WES has not been exhausted and that causal coding 
variants are often missed due to inappropriate correction of noise in the data, 
insufficient use of clinical (phenotypic) data, or reporting of long un-ranked 
candidate lists, requiring tedious screening by clinicians. We further claim that 
these shortcomings are often overlooked due to unrealistic simulated benchmark 
tests not reflecting the level of noise found in real family or trio NGS data.  
We have addressed these problems by developing eDiVA, a pipeline that combines 
multi-sample variant calling of family data, QC and filtering, extensive functional 
annotation, machine learning based classification of deleterious variants and 
prioritization of causal variants optimized for various clinical scenarios. 
Furthermore, we developed a highly realistic benchmark test combining real WES 
data of a parent-child trio with thousands of pathogenic ClinVar variants to 
generate 6,811 semi-synthetic disease trios. Using these cases, we have 
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demonstrated that eDiVA’s pathogenicity estimator (eDiVA-Score) as well as 
eDiVA’s prioritization algorithm perform favorably compared to existing state-of-
the-art methods. eDiVA has been able to find disease causing variants with higher 
recall, fewer false positives and better ranking than competing tools in three 
benchmarked modes of inheritance. Finally, we evaluated the use of phenotypic 
descriptors for optimizing the prioritization process.  
We found that adding HPO IDs based prioritization introduces a trade-off between 
recall and the number of false positives in the output list. Despite the marginal 
reduction in recall, focusing on known disease genes is often the preferred choice 
for diagnostic purposes. Our knowledge of genetic factors playing a role in disease 
is constantly growing, reflected in a rapid increase of genotype-phenotype relations 
stored in various databases. Hence, it would be beneficial to re-analyze WES 
datasets once in a while (e.g. every 6-12 months) to benefit from new knowledge 
and to facilitate identification of previously unknown/unreported causal variants. 
Moreover, combined re-analysis of the growing cohorts of WES data stored in 
many institutes would allow to identify matching causal genes across multiple 
families or cases. However, most analysis pipelines require substantial hands-on 
time and long candidate variant lists have to be screened by experts, making 
regular re-analysis of datasets impractical. eDiVA has been developed with a 
specific emphasis on high reproducibility of results and complete automation of the 
analysis using artificial intelligence based methods. Machine learning classifiers 
are employed to perform candidate ranking and prioritization, reducing hands-on 
time of clinical experts to a minimum. Integration with NextFlow, moreover, 
guarantees reproducibility of results at later time points and on most computing 
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platforms. Therefore, eDiVA is a dedicated solution for regular re-analysis of large 
disease cohorts or collections of diagnostic cases.  
Additional steps can be taken in order to improve the identification of disease-
related variants from WES data. The availability of custom allele frequency 
databases with geographical specificity would help to reduce the number of false 
positive genotype-phenotype associations due to population specific variants. To 
this end, institutes and hospitals with access to large cohorts of sequenced exomes 
may use in-house data to filter population specific variants, an approach we have 
pursued our self by collecting thousands of Iberian cases in an aggregated allele 
frequency database (http://geevs.crg.eu/, unpublished). Identification of extended 
homozygosity regions could in addition help to diagnose causal homozygous 
variants in consanguineous cases. Moreover, the integration of structural and copy 
number variants (SVs and CNVs) has been shown to increase recall rates 
substantially (Gambin et al., 2017). Despite their frequent involvement in rare 
diseases (McCarroll and Altshuler, 2007), CNVs are often disregarded in WES 
analyses, and are rarely processed in combination with point mutations. 
Prioritization algorithms will have to be adapted to consider compound 
heterozygotes composed of a point mutation in one and a CNV in the other allele. 
CNV analysis is currently being integrated in eDiVA and will be available in the 
near future.  
Better use of phenotypic descriptors has the potential to improve both precision and 
recall of causal variant prioritization methods. We observed that HPO IDs based 
prioritization dramatically improved the precision of eDiVA. However, incomplete 
maps of known genotype-phenotype (or gene-phenotype) relations in public 
databases led to a mild reduction in recall. Robinson et al. (Robinson et al., 2014) 
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proposed a method to overcome this limitation, tapping into the genotype-
phenotype associations from mouse data to solve causal variant identification for 
corresponding human phenotypes. Other methods based on image analysis, e.g. 
Hadj Rabia et al. (Hadj-Rabia et al., 2017) or face2gene 
(http://suite.face2gene.com/), have also shown promising results for diagnosis of 
patients with visible phenotypic features. Finally, an important step in the 
evaluation of newly discovered genotype-phenotype associations is the 
identification of additional cases with a similar phenotype and mutations in the 
same gene. Several approaches for gene matching have been published, e.g. 
GeneMatcher (Sobreira et al., 2015), which have been connected via the 
Matchmaker Exchange platform. Integration of approaches using image analysis, 
cross-species phenotype-genotype correlation, and gene matching has the potential 
to further improve AI based variant prioritization methods such that they can rival 
the diagnostic precision of clinical experts in the future.  
In summary, we have shown that eDiVA is a step towards full automation of causal 
variant identification in family and parent-child trio data using machine-learning 
based approaches. eDiVA can be used as a support tool for clinicians to find 
disease-causing variants, or as a fully automated solution for periodic re-analysis of 
large WES (or WGS) cohorts. eDiVA is able to identify known causal disease 
variants with high precision and recall, and facilitates identification of novel 
disease variants with minimal hands-on time. 
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Figures 
Figure 1: eDiVA-Score random forest model. A): estimated importance of features 
used in the model (extracted with varImp command). B): distribution of values for 
the top-9 features used in the model, comparing ClinVar pathogenic against 
ClinVar non-pathogenic variants. 
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Figure 2: Benchmarking of the pathogenicity classifiers eDiVA-Score, CADD, 
Eigen, Revel, and M-CAP using ROC for A) set of 10,494 ClinVar pathogenic 
variants (TP) and 3,887 ClinVar ‘benign’ variants (TN), B) set of 16,694 ClinVar 
pathogenic variants (TP) and 19,888 ClinVar ‘benign’ variants (TN), setting 
missing values to benign, C) subset of rare variants (AF<1%) from set B, D) set of 
63,712 variants from HGMD (TP) and 100,000 from GnomAD (TN) for which 
values from all tools are available E) set of 96,569 variants from HGMD (TP) and 
100,000 from GnomAD (TN), setting missing values to benign, F) subset of rare 
variants (AF<1%) from set E, G) set of 63,712 HGMD variants (‘DM’ and ‘DM?’) 
as TP, and 1,892 HGMD variants (other categories) as TN for which values from 
all tools are available, H) set of 96,569 variants from HGMD (‘DM’ and ‘DM?’) as 
TP, and 7,376 HGMD (other categories) as TN, setting missing values to benign, 
and I) subset of rare variants (AF<1%) from set H. 
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Figure 3: ROC curves comparing pathogenicity classifiers on five independent 
datasets (and the combined set) composed of pathogenic and neutral variants. 
Revel, M-CAP and eDiVA show a similarly strong performance, with the 
exception of the PredictSNP and Varibench sets, on which Revel and M-CAP 
outperform eDiVA-Score. 
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Figure 4: Benchmark of the causal variant prioritization tools eDiVA, Exomiser, 
Phen-Gen and PhenoDB. A) Violin plots showing the rank of disease-causing 
variants within the reported candidate lists for the three tested inheritance types: 
“recessive homozygous”, “compound heterozygous”, and “dominant de novo”, B) 
Recall values for 6811 semi-synthetic trio cases, representing the fraction of 
identified causal variants (i.e. ‘solved cases’). C) Average number of false positives 
reported per case as a proxy for precision. eDiVA has been tested in two 
configurations, with HPO-based gene prioritization (eDiVA_HPO) and with the 
default configuration not using HPO terms (eDiVA). Adding HPO filtering reduces 
false positives at the cost of a slightly reduced Recall. 
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